Abstracts Archive - Page 725 of 2607 - ACR Meeting Abstracts

Abstract Number: 1942 • ACR Convergence 2021
Occurrence of Basal Cell and Squamous Cell Carcinomas of the Skin Under Different DMARD Therapies
Imke Redeker¹, Peter Herzer², Cornelia Kühne³, Ilka Schwarze⁴, Martin Schaefer⁵ and Anja Strangfeld⁶, ¹German Rheumatism Research Centre (DRFZ), Berlin, Germany, ²Scientific Advisory Board, Munich, Germany, ³Rheumatologist, Haldensleben, Germany, ⁴Rheumatologist, Leipzig, Germany, ⁵German Rheumatism Research Center, Berlin, Germany, ⁶Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany
Background/Purpose: Squamous and basal cell carcinomas are the most common malignancies of the skin; they are subsumed under non-melanoma skin cancer (NMSC). The risk of…
Abstract Number: PP01 • ACR Convergence 2021
Unicycling for a Cure: My UNIque Physical Activity Intervention for Rheumatoid Arthritis During the COVID19 Pandemic
Dana Guglielmo, San Diego, CA
Background/Purpose: I was diagnosed with rheumatoid arthritis at age 17. In my 20s, I joined Racing For A Cure of the Arthritis National Research Foundation,…
Abstract Number: PP05 • ACR Convergence 2021
Fighting Health-Related Misinformation Using Social Media / How Creating an Online Group for Patients with Relapsing Polychondritis — and Moderating It with Health Professionals — Helps Spread Reliable and Empowering Information
Michael Linn¹, Spenser Mestel² and Susie Ratledge³, ¹Relapsing Polychondritis Foundation, New York, NY, ²New York, NY, ³Relapsing Polychondritis: Secular Science and Support group, Chattanooga, TN
Background/Purpose: Before I became ill in 2017, I was a registered nurse with a degree in health science who'd often educate patients about how they…
Abstract Number: PP03 • ACR Convergence 2021
Navigating Maintenance of a Rare Autoimmune Rheumatic Disease in the Context of the COVID-19 Pandemic
Ida Hakkarinen, Greenbelt, MD
Background/Purpose: On March 13th, 2020, the President of the United States issued a proclamation declaring that the outbreak of coronavirus disease 2019 (COVID-19) was a…
Abstract Number: 1946 • ACR Convergence 2021
Therapeutic Drug Monitoring Compared to Standard Infliximab Therapy in Patients with Immune-mediated Inflammatory Diseases: A Randomized Controlled Trial
Silje Watterdal Syversen¹, Guro Goll¹, Kristin Jørgensen², Marthe Brun¹, Øystein Sandanger³, Kristin Hammersbøen², Joseph Sexton¹, Inge Olsen³, Johanna Gehin⁴, David Warren³, Rolf Anton Klaasen³, Trude Bruun⁵, Maud Kristine Ljoså⁶, Anne Haugen⁷, Rune Njålla⁸, Brigitte Michelsen⁹, Camilla Zettel¹⁰, Yngvill Bragenes¹¹, Svanaug Skorpe¹², Eldri Strand¹³, Pawel Mielnik¹⁴, Cato Mørk¹⁵, Tore Kvien¹, Jørgen Jahnsen², Nils Bolstad¹⁶ and Espen Haavardsholm¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Akershus University Hospital, Lørenskog, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Oslo University Hospital, Lillehammer, Nepal, ⁵The University Hospital of North Norway, Tromsø, Norway, ⁶Dept. of Rheumatology, Ålesund Hospital, Ålesund, Norway, ⁷Østfold Hospital Trust, Moss, Norway, ⁸Nordland Hospital Trust, Bodø, Bodø, Norway, ⁹Hospital of Southern Norway Trust, Kristiansand, Norway, ¹⁰Betanien Hospital, Skien, Norway, ¹¹Vestre Viken Hospital Trust, Drammen, Norway, ¹²Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, ¹³Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ¹⁴Førde Hospital Trust, Førde, Norway, ¹⁵Akershus Dermatology Center, Lørenskog, Norway, ¹⁶Oslo University Hospital, Radiumhospitalet, Oslo, Norway
Background/Purpose: Proactive therapeutic drug monitoring (TDM), a treatment strategy based on scheduled assessments of serum drug levels, has been proposed to optimize efficacy and safety…
Abstract Number: 1940 • ACR Convergence 2021
Malignancies in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Jeffrey Curtis¹, Kunihiro Yamaoka², Yi-Hsing Chen³, Levent M Gunay⁴, Naonobu Sugiyama⁵, Carol A Connell⁶, Cunshan Wang⁶, Joseph Wu⁶, Sujatha Menon⁶, Ivana Vranic⁷ and Juan J Gomez-Reino⁸, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²School of Medicine, Department of Rheumatology and Infectious Diseases, Kitasato University, Sagamihara, Japan, ³Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ⁴Pfizer Inc, Istanbul, Turkey, ⁵Pfizer Japan Inc, Tokyo, Japan, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Tadworth, Surrey, United Kingdom, ⁸Hospital Clínico Universitario, Santiago de Compostela, Spain
Background/Purpose: ORAL Surveillance (NCT02092467) was a post-authorization safety study to assess the relative risk of tofacitinib vs TNF inhibitors (TNFi), based on observed increases in…
Abstract Number: PP11 • ACR Convergence 2021
“Our Arthritis May Be Chronic but We Are Definitely Iconic” – Two Teens Created a National Podcast for Youth with Rheumatic Diseases
Trishtha Peters¹ and Natasha Trehan², ¹University of Ontario, Toronto, ON, Canada, ²University of Ottawa, Toronto, ON, Canada
Background/Purpose: Trish Peters was diagnosed with JIA at 11. She has been on Methotrexate to lessen disease activity for her knees and hands. She does…
Abstract Number: PP10 • ACR Convergence 2021
Discovering ‘I’ Through Interaction with Support Group Members: A Place of Empathy That Transcends the Limitations of Words
Noriko Okochi¹, Eiji Oishi² and Mika Ishiguro¹, ¹Rheumatic Disease and Vasculitis Support Network Japan, Tokyo, Japan, ²Rheumatic Disease and Vasculitis Support Network Japan, Yamaguchi, Japan
Background/Purpose: Since 5-year-old, I have had unexplained symptoms. At the age of 13, my whole body became inflamed. The pain was so intense that I…
Abstract Number: PP06 • ACR Convergence 2021
Collaborative Advocacy Helps Me and Other Patients With Relapsing Polychondritis (“RP”’) / My life improved by helping the RP Foundation and Race for RP facilitate awareness, education, and research to improve the quality of life for patients with RP and advance a cure for this disease.
Michael Linn¹ and Dan Smith², ¹Relapsing Polychondritis Foundation, New York, NY, ²Relapsing Polychondritis Foundation, Canton, MI
Background/Purpose: In March 2020, I was diagnosed as having relapsing polychondritis ("RP"), an understudied, underdiagnosed, and undertreated debilitating autoimmune disease that can be fatal if…
Abstract Number: PP13 • ACR Convergence 2021
CreakyKitchen: How the Online Cooking Show I Started is Building Community and Encouraging Better Food Choices for Me and Others Living with Rheumatic and Chronic Disease
Chantelle Marcial, Boston, MA
Background/Purpose: At 19, I was mis-diagnosed with Lupus as it was a common condition in my family. My treatment at that time was mainly DMARDs,…
Abstract Number: PP12 • ACR Convergence 2021
Fighting for the Care We Deserve: My Experience as a Latina Patient-Researcher During the COVID-19 Pandemic
Guadalupe Torres¹, Courtney Wells² and Kristine Carandang³, ¹, ²University of Wisconsin-River Falls, School of Social Work, St. Paul, MN, ³Global Healthy Living Foundation, CreakyJoints, San Diego, CA
Background/Purpose: I am a 23-year-old first generation Latina with rheumatoid arthritis (RA). Despite being disproportionately affected by rheumatic conditions, the perspectives of Latinx remain poorly…
Abstract Number: PP09 • ACR Convergence 2021
Family Planning while Living with Rheumatoid Arthritis
Shannan O'Hara-Levi, Monroe, NY
Background/Purpose: Over the course of my 30+ years living with Polyarticular Juvenile Rheumatoid Arthritis, I have never had long term success on any one biologic treatment,…
Abstract Number: 1943 • ACR Convergence 2021
Post-inflammatory and Degenerative Changes in Patients with Psoriatic Arthritis and Axial Manifestations: Post-hoc Analysis from a Double-blind, Randomized, Phase 3b Trial
Xenofon Baraliakos¹, Effie Pournara², Laura Coates³, Victoria Navarro-Compán⁴, Roisin White⁵, Barbara Schulz² and Robert Landewé⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁴Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ⁵Novartis Ireland Limited, Dublin, Ireland, ⁶Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands
Background/Purpose: Axial psoriatic arthritis (PsA) is the only one of the PsA manifestations, still not clearly defined, with no currently available universally acceptable clinical and…
Abstract Number: 1916 • ACR Convergence 2021
Antibodies to Malondialdehyde-Acetaldehyde (MAA) Modified Proteins Predict Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease
Bryant England¹, Geoffrey Thiele¹, Dana Ascherman², Michael Duryee¹, Carlos Hunter¹, Yangyuna Yang¹, Punyasha Roul¹, Harlan Sayles¹, Andreas Reimold³, Gail Kerr⁴, Joshua Baker⁵, Jill Poole¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA, ³University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ⁴Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Because interstitial lung disease (ILD) causes substantial morbidity and mortality in rheumatoid arthritis (RA), there is a need for methods to facilitate early identification…
Abstract Number: 1870 • ACR Convergence 2021
Comparative Study on Anti-TNF vs Tocilizumab for Treatment of Refractory Uveitic Cystoid Macular Edema Due to Behcet’s Disease: Multicenter Study of 49 Patients
Belén Atienza-Mateo¹, Iván Ferraz-Amaro², Emma Beltrán Catalán³, Alfredo Adán⁴, Marisa Hernandez Garfella⁵, Lucía Martínez-Costa⁶, Miguel Cordero Coma⁷, Manuel Diaz-Llopis⁸, José M. Herreras⁹, Ana Blanco¹⁰, Ignacio Torre¹¹, David Díaz-Valle¹², Antonio Atanes-Sandoval¹³, Felix Hernandez¹⁴, Santos Insua¹⁵, Julio Sánchez¹⁶, raquel almodovar¹⁷, Oscar Ruiz-Moreno¹⁸, Myriam Gandia Martinez¹⁹, Joan M. Nolla²⁰, José Luis Martin-Varillas²¹, Vanesa Calvo-Río²², Diana Prieto-Peña²³, Miguel Ángel gonzalez-Gay²⁴ and Ricardo Blanco²², ¹Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ³Hospital del Mar, Barcelona, Spain, ⁴Hospital Clinic, Barcelona, Spain, ⁵Hospital General Universitario de Valencia, Valencia, Spain, ⁶Hospital Peset, Valencia, Valencia, Spain, ⁷Hospital de León, Leon, Spain, ⁸Hospital Universitario La Fe, Valencia, Spain, ⁹Hospital Universitario IOBA, Valladolid, Spain, ¹⁰Hospital Universitario de Donostia, San Sebastián, ¹¹Hospital Universitario de Basurto, Bilbao, Spain, ¹²Hospital Clínico San Carlos, Madrid, Madrid, Spain, ¹³Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹⁴Hospital Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain, ¹⁵Hospital Universitario Santiago de Compostela, A Coruña, Spain, ¹⁶Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁷Hospital Universitario Fundación de Alcorcón, Madrid, Spain, ¹⁸Hospital Universitario Miguel Servet, Zaragoza, Zaragoza, Spain, ¹⁹Hospital Puerta del Mar, Cádiz, Spain, ²⁰Hospital Universitario de Bellvitge, Barcelona, Barcelona, Spain, ²¹Hospital Sierrallana, Torrelavega, Spain, ²²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²³Hospital Universitario Marqués de Valdecilla, santander, Spain, ²⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Posterior segment involvement is the most serious affection of uveitis in Behçet’s disease (BD), with cystoid macular edema (CME) being the leading cause of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].